Bacitracin
- Atc Codes:D06AX05#J01XX10#R02AB04
- CAS Codes:1405-89-6#1405-87-4
- PHARMGKB ID:1405-89-6#1405-87-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Portugal: Bacitracina.
North America
Canada: Baciguent, Baciject; USA: Baciguent, BaciiM, Baci-Rx.
Drug combinations
Bacitracin and Neomycin
Bacitracin and Polymyxin B
Bacitracin, Hydrocortisone and Polymyxin B
Bacitracin, Neomycin, and Polymyxin B
Bacitracin, Neomycin, and Tyrothricin
Bacitracin, Hydrocortisone, Neomycin, and Polymyxin B
Bacitracin, Neomycin, Polymyxin B, and Pramoxine
Other Bacitracin combinations: Cysteine
Chemistry
Bacitracin Methylene Disalicylate.
Bacitracin Zinc: Bacitracins, zinc complex. CAS-1405-89-6. CAS-1405-87-4 (bacitracin).
Pharmacologic Category
Miscellaneous Antibacterials; Bacitracins. (ATC-Code: D06AX05; J01XX10; R02AB04).
Mechanism of action
Inhibits bacterial cell wall synthesis.
Therapeutic use
Infections by Gram-positive bacilli.
Pregnancy and lactiation implications
Use with caution during lactation or pregnancy.
Unlabeled use
Antibiotic-associated colitis. Enteric elimination of vancomycin-resistant enterococci.
Contraindications
Hypersensitivity to bacitracin or any component of the formulation. I.M. use contraindicated in renal impairment.
Warnings and precautions
Renal failure may occur due to tubular and glomerular necrosis. Fungal/bacterial superinfection after prolonged use (i.e. Clostridium difficile-associated diarrhea and pseudomembranous colitis). Do not administer I.V. (risk of severe thrombophlebitis).